Prothena Corporation plc
PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb cliniā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.88
Price+0.23%
$0.02
1Y
Price
Market Cap
$464.897m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+65.9%
EBITDA Margin+64.1%
Net Profit Margin+56.5%
Free Cash Flow Margin+65.9%
EBITDA Margin+64.1%
Net Profit Margin+56.5%
Free Cash Flow MarginRevenue
$57.940m
+498.3%
1y CAGR+151.1%
3y CAGR+130.7%
5y CAGREarnings
-$151.176m
+38.1%
1y CAGR-14.9%
3y CAGR-17.6%
5y CAGREPS
-$2.82
+37.8%
1y CAGR-14.7%
3y CAGR-13.9%
5y CAGRBook Value
$312.616m
$349.894m
Assets$37.278m
Liabilities$7.654m
DebtDebt to Assets
2.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$81.436m
+50.3%
1y CAGR+10.5%
3y CAGR+1.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company